Johannes Pulst-Korenberg, MD
Neurocritical Care · Los Angeles, CANPI 1558772368
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,420 of the $12,041 with a category attached, or 78.2%. Amgen accounts for 75.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $9,678 and has fallen 79.1% since, to $2,021 in 2025. Among neurocritical care clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $415.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$9K
- AstraZeneca$2K
- Novartis$261
- TG Therapeutics, Inc.$157
- Teva Pharmaceuticals USA, Inc.$125
- Johnson & Johnson$109
- plus $70 from 2 others
What the payments were for
- Consulting fees$9,42078%
- Travel & lodging$1,0008%
- Food & beverage$1,57613%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $9,036 |
| AstraZeneca | 6 | $2,283 |
| Novartis | 3 | $261 |
| TG Therapeutics, Inc. | 2 | $157 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $109 |
| Biogen | 1 | $39 |
| EMD Serono, Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,041 in reported general payments places this provider in the 90th percentile of 65 neurocritical care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 13 | $17,104 |
Paid to pharmacies, not to this prescriber.
Other neurocritical care in Los Angeles
- Nerses SanossianLos Angeles$106K
- May Kim-TenserLos Angeles$29K
- Shouri LahiriLos Angeles$6K
- Fawaz TarziLos Angeles$2K
- Charlotte ZhongLos Angeles$1K
- Benjamin EmanuelLos Angeles$270
- Grace KuoLos Angeles$269
- Benjamin StuartLos Angeles$240
- Adriana Rosero EnriquezLos Angeles$157
- Sebina BulicLos Angeles$147
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.